PIK3CA and endometrial cancer: The mutational landscape observed was typical for an endometrial cancer cohort [2]: TP53 mutated (54.8% of tumors), PIK3CA (38.0%), PTEN (21.4%), KRAS (26.2%), and KMT2D and ARID1A (19.0% each) (Fig. 2A).